CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that its chief executive officer, David Giljohann, will give a company update on Wednesday, March 4, 2020 at 11:20 AM ET at the Cowen 40th Annual Healthcare Conference in Boston.
Presentation and Breakout Session Details:
Cowen 40th Annual Health Care Conference
Date: Wednesday, March 4, 2020
Presentation Time: 11:20-11:50 AM Eastern Time
A live audio webcast will be available on the Investors section of Exicure’s website: www.exicuretx.com. The webcast will be archived for approximately 30 days following the event.
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure's lead program is in a Phase 1b/2 trial in patients with advanced solid tumors. Exicure is based outside of Chicago, IL and in Cambridge, MA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200302005191/en/
Source: Exicure, Inc.